scholarly journals No Compelling Evidence that Preferences for Facial Masculinity Track Changes in Women’s Hormonal Status

2018 ◽  
Vol 29 (6) ◽  
pp. 996-1005 ◽  
Author(s):  
Benedict C. Jones ◽  
Amanda C. Hahn ◽  
Claire I. Fisher ◽  
Hongyi Wang ◽  
Michal Kandrik ◽  
...  
Keyword(s):  
Contraceptive Use ◽  
Steroid Hormone ◽  
Hormonal Status ◽  
Compelling Evidence ◽  
Short Term ◽  
Facial Masculinity ◽  
Oral Contraceptive Use ◽  
Within Subjects ◽  
Women’S Preferences

Although widely cited as strong evidence that sexual selection has shaped human facial-attractiveness judgments, findings suggesting that women’s preferences for masculine characteristics in men’s faces are related to women’s hormonal status are equivocal and controversial. Consequently, we conducted the largest-ever longitudinal study of the hormonal correlates of women’s preferences for facial masculinity ( N = 584). Analyses showed no compelling evidence that preferences for facial masculinity were related to changes in women’s salivary steroid hormone levels. Furthermore, both within-subjects and between-subjects comparisons showed no evidence that oral contraceptive use decreased masculinity preferences. However, women generally preferred masculinized over feminized versions of men’s faces, particularly when assessing men’s attractiveness for short-term, rather than long-term, relationships. Our results do not support the hypothesized link between women’s preferences for facial masculinity and their hormonal status.

scholarly journals No compelling evidence that preferences for facial masculinity track changes in women’s hormonal status

2017 ◽  
Author(s):  
Benedict C Jones ◽  
Amanda C Hahn ◽  
Claire I Fisher ◽  
Hongyi Wang ◽  
Michal Kandrik ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Steroid Hormone ◽  
Hormonal Status ◽  
Compelling Evidence ◽  
Short Term ◽  
Facial Masculinity ◽  
Oral Contraceptive Use ◽  
Women’S Preferences

AbstractAlthough widely cited as strong evidence that sexual selection has shaped human facial attractiveness judgments, evidence that preferences for masculine characteristics in men’s faces are related to women’s hormonal status is equivocal and controversial. Consequently, we conducted the largest ever longitudinal study of the hormonal correlates of women’s preferences for facial masculinity (N=584). Analyses showed no compelling evidence that preferences for facial masculinity were related to changes in women’s salivary steroid hormone levels. Furthermore, both within-subject and between-subject comparisons showed no evidence that oral contraceptive use decreased masculinity preferences. However, women generally preferred masculinized over feminized versions of men’s faces, particularly when assessing men’s attractiveness for short-term, rather than long-term, relationships. Our results do not support the hypothesized link between women’s preferences for facial masculinity and their hormonal status.

scholarly journals No evidence that women using oral contraceptives have weaker preferences for masculine characteristics in men’s faces

2018 ◽  
Author(s):  
Benedict C Jones ◽  
Lisa Marie DeBruine ◽  
Amanda Hahn
Keyword(s):  
Steroid Hormones ◽  
Oral Contraceptives ◽  
Large Scale ◽  
Contraceptive Use ◽  
Reproductive Hormones ◽  
Small Samples ◽  
Facial Masculinity ◽  
Oral Contraceptive Use ◽  
Heterosexual Women ◽  
Women’S Preferences

Previous research has suggested that women using oral contraceptives show weaker preferences for masculine men than do women not using oral contraceptives. Such research would be consistent with the hypothesis that steroid hormones influence women’s preferences for masculine men. Recent large-scale longitudinal studies, however, have found limited evidence linking steroid hormones to masculinity preferences. Given the relatively small samples used in previous studies investigating putative associations between masculinity preferences and oral contraceptive use, we compared the facial masculinity preferences of women using oral contraceptives and women not using oral contraceptives in a large online sample of 6482 heterosexual women. We found no evidence that women using oral contraceptives had weaker preferences for male facial masculinity than did women not using oral contraceptives. These findings add to a growing literature suggesting that links between reproductive hormones and preferences are more limited than previously proposed.

Hepatocellular carcinoma in long-term oral contraceptive use

2008 ◽  
Vol 16 (6) ◽  
pp. 372-376 ◽  
Author(s):  
M. Isabel Fiel ◽  
Albert Min ◽  
Michael A. Gerber ◽  
Bridget Faire ◽  
Myron Schwartz ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Oral Contraceptive Use

Abstract 3002: Long Term Oral Contraceptive Use is an Independent Risk Factor for Arterial Stiffening

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Ernst Rietzschel ◽  
Marc De Buyzere ◽  
Patrick Segers ◽  
Sofie Bekaert ◽  
Dirk De Bacquer ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Contraceptive Use ◽  
Hormone Replacement ◽  
Lipid Lowering ◽  
Oral Contraceptive Use ◽  
Arterial Tonometry ◽  
Blood Pressures ◽  
The Difference ◽  
Population Effects

Oral contraceptives (OC) are among the most frequently used drugs in the world with approximately 100 million women worldwide taking OC. In contrast to the active controversy surrounding hormone replacement therapy, little attention has been focused on OC, a drug therapy taken by far more women for far longer time periods. We describe the population effects of current and long-term OC exposure on a prognostically well validated marker of arterial stiffness: carotid-femoral pulse wave velocity (PWV). The Asklepios study is a representative sample (2524 apparently healthy M/F volunteers, aged 35–55 years, 1301 women) from the Belgian general population, free from overt cardiovascular disease. The subjects were extensively screened (biochemistry, lifestyle, cardiac and vascular echography, arterial tonometry). PWV was measured from flow patterns registered by Doppler echography in the femoral and carotid arteries. Of 1301 women (median age 45.7 y), 27.4% were actively taking OC. In contrast past use of OC is far more prevalent with 81% of women having taken OC for at least 1 year. The median duration of exposition in these women was 13 years. Age-adjusted PWV was higher in women currently taking OC: 6.75 versus 6.55 m/s (difference 0.19 ± 0.09 m/s; p = 0.034). However, current OC users also had higher blood pressures (BP): systolic BP (+4.4 ± 0.9 mmHg; p < 0.001), diastolic BP (+2.3 ± 0.6 mmHg; p < 0.001). After adjustement for BP, the difference in PWV between current OC users and non-users became non-significant: 6.60 versus 6.62 m/s (difference 0.02 ± 0.09 m/s; p = 0.814). In contrast, duration of OC use is a significant determinant of PWV, even after adjustement for age, BP, lipid levels, body size, heart rate, drug therapy (lipid-lowering, antihypertensive), glycemic status and smoking: F = 6.1; p = 0.013. Per 10 years of OC exposure PWV increased by 0.1 m/s (0.02– 0.18; p = 0.013). Use of OC is associated with increased vascular stiffness in women. Current use is associated with increased PWV because OC’s increase blood pressure, long-term use (probably through structural remodelling of the vessels) is an independent determinant of PWV, increasing PWV by 0.10 m/s per 10 years exposure.

scholarly journals Association Between Past Oral Contraceptive Use and the Prevalence of Hypertension in Postmenopausal Women: The Fifth (2010–2012) Korea National Health and Nutrition Examination Survey (KNHANES V)

2021 ◽  
Author(s):  
JungJu Lee ◽  
Hyunsuk Jeong ◽  
Joo Hee Yoon ◽  
Hyeon Woo Yim
Keyword(s):  
Postmenopausal Women ◽  
National Health ◽  
Contraceptive Use ◽  
Confounding Factors ◽  
Nutrition Examination Survey ◽  
Short Term ◽  
Multivariable Logistic Regression Model ◽  
Cross Sectional ◽  
Health And Nutrition

Abstract Background: There is little evidence as to whether the use of oral contraceptives(OC) during the fertile years affects the development of postmenopausal hypertension. This study aimed to evaluate the effects of past use of OC on the development of hypertension in postmenopausal women. Methods: This was a cross-sectional study conducted using data from the Fifth Korea National Health and Nutrition Examination Survey of postmenopausal women. Subjects were classified into three groups based on past OC use duration: nonusers, short-term users(0–30months), and long-term users(≥30 months). We evaluated the development of hypertension in women after menopause. A multivariable logistic regression model was used to identify the association between the use of OC during the fertile years and the prevalence of hypertension after menopause following adjustment for potential confounding factors. Results: Of the 3,386 postmenopausal women, 2,713 were nonusers of OC, 489 were short-term users, and 184 were long-term users. Women who had used OC for 30 months or more had a significantly greater prevalence of hypertension after menopause than those who had never taken OC. The association between taking OC for 30 months or more during the fertile years and the prevalence of hypertension after menopause was significant following adjustment for potential confounding factors (aOR:1.92; 95%CI:1.22–3.00). Conclusion: This study identified an association between past OC use and an increased prevalence of hypertension in postmenopausal women. Our results suggest that long-term use of OC during the fertile years can be an important risk factor for subsequent hypertension after menopause.

Postscript: starting oral contraceptives (25 May, page 41)

1992 ◽  
Vol 30 (14) ◽  
pp. 56.1-56
Keyword(s):  
Breast Cancer ◽  
Oral Contraceptives ◽  
Contraceptive Use ◽  
Causal Relation ◽  
Case Control ◽  
Term Pregnancy ◽  
Oral Contraceptive Use ◽  
Increased Risk ◽  
The Uk

In our article on oral contraceptives (OCs) we state that ‘oral contraceptives increase the risk of breast cancer with long-term use but reduce the risk of endometrial and ovarian cancer’. Some commentators have questioned the breast cancer risk. The UK National Case-Control (UKNCC) study, which looked at oral contraceptive use in women with breast cancer diagnosed before age 36, found a trend for increased risk associated with duration of use.1 ‘The simplest and most plausible explanation’, say the authors of the study, ‘must be that there is a substantial causal relation between prolonged use and breast cancer in young women.’ The increased risk seems to be associated particularly with OC use before the first full-term pregnancy.2 Several studies found no excess risk in OC users aged 45 or over, few of whom had taken the pill before their first pregnancy.3–5 In the UKNCC study the relative risk of breast cancer was 1.43 after 4–8 years’ use and 1.74 after more than 8 years’ use. In broad terms this means that three women in 1000 who use oral contraceptives for 4 or more years might be expected to be under treatment for breast cancer by age 36, compared with two per 1000 non-users.

Sign in / Sign up

Export Citation Format

Share Document